S. Stumm

Paclitaxel Treatment of Breast Cancer Cell Lines Modulates Fas/Fas Ligand Expression and Induces Apoptosis Which Can Be Inhibited through the CD40 Receptor

B. Gückel, D. Wallwiener, M. Lindner, 2004, Oncology.

Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.

B. Gückel, S. Stevanović, D. Wallwiener, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions.

B. Gückel, D. Wallwiener, R. Batrla, 2002, Cancer research.

Differential effects on innate versus adaptive immune responses by WF10.

T. Giese, M. McGrath, S. Meuer, 2004, Cellular immunology.

Ethical evaluation of related donation: the donor after five years.

R. Simmons, S. Stumm, L. Kamstra-Hennen, 1981, Transplantation proceedings.

A CD80-transfected human breast cancer cell variant induces HER-2/neu–specific T cells in HLA-A*02–matched situations in vitro as well as in vivo

B. Gückel, D. Wallwiener, A. Marmé, 2005, Cancer Immunology, Immunotherapy.

A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry.

B. Gückel, H. Rammensee, S. Stevanović, 2001, Cancer research.

A MAGE-A 1 HLA-A * 0201 Epitope Identified by Mass Spectrometry 1

B. Gückel, H. Rammensee, S. Stevanović, 2001 .

Mutation of a phosphorylation site in the DNA-binding domain is required for redox-independent transactivation of AP1-dependent genes by v-Jun.

P. Angel, D. Gillespie, A. Pintzas, 1993, Oncogene.